I never understood the relationship between the heart and lungs before I was diagnosed with idiopathic pulmonary fibrosis (IPF) in 2016. As if learning my lungs would fail from this condition wasn’t hard enough to accept, I was also assigned a cardiologist to monitor my heart health, which is often…
The Importance of Managing Heart Health With Interstitial Lung Disease
Scientists have developed a new lab-grown three-dimension (3D) microtissue model that replicates the key features of the idiopathic pulmonary fibrosis (IPF) microenvironment better than other cellular and animal models, and that enables more robust screening of potential therapies. When the model was generated using lung cells collected from IPF…
In my previous column, I described the roller-coaster ride of my lung transplant evaluation. On Aug. 7, 2020, six years after my diagnosis of idiopathic pulmonary fibrosis (IPF), I was officially placed on the transplant list. Waiting for the call Waiting for the call was both breathtaking…
Reviva Pharmaceuticals is planning to seek the U.S. Food and Drug Administration’s (FDA) permission to begin Phase 2 clinical trials testing its investigational therapy brilaroxazine in people with idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). “We … expect to begin regulatory submissions to the FDA…
An inhalable therapeutic is being developed using pressure-treated yeast beta-glucan for people with COVID-19 as well as other severe lung diseases, including idiopathic pulmonary fibrosis (IPF). Beta-glucans are fiber compounds that are naturally found in the cell walls of grains, bacteria, and fungi, such as yeast. Ceapro, a biotechnology…
The Microbiome Therapeutics Innovation Group (MTIG), a coalition of companies working to develop U.S. Food and Drug Administration (FDA)-microbiome-based therapies, announced the addition of Alveolus Bio to its group. Alveolus has more than a decade of research into neutrophilic inflammation — an asthmatic inflammation driven by specific white…
Last week, I wrote a column about needing to slow down as a patient living with idiopathic pulmonary fibrosis (IPF). Since its publication, I have spent a lot of time strategizing about how to do that. I am often guilty of saying I need to do something but neglecting…
Alterations in lactic acid metabolism — part of the process that allows the body to produce energy in the absence of oxygen — were found in lung tissues collected from patients with idiopathic pulmonary fibrosis (IPF), a recent study reported. These findings suggest that lactic acid metabolism may be…
Today’s inspiration comes from a brainstorming session I had with fellow columnists. Speaking with other people who live with rare diseases made me think about what I wanted to express in my column. I realized I feel a lot of guilt, for several reasons. Watching others struggle with PF…
High-flow nasal cannula oxygen therapy (HFNC) increases exercise tolerance — improving endurance times and reducing leg fatigue — in adults with stable idiopathic pulmonary fibrosis (IPF) having exercise-induced low blood oxygen levels, according to a small trial in Japan. Notably, HFNC’s benefits were superior to those of standard oxygen therapy,…
